The Neisseria meningitidis macrophage infectivity potentiator protein induces cross-strain serum bactericidal activity and is a potential serogroup B vaccine candidate

Infection and Immunity

Volumn 79, Issue 9, 2011, Pages 3784-3791

  Hung, Miao Chiu ^a   Salim, Omar ^a   Williams, Jeannette N ^a   Heckels, John E ^a   Christodoulides, Myron ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; BACTERIUM ANTIBODY; MACROPHAGE INFECTIVITY POTENTIATOR VACCINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; INFECTION PREVENTION; LEGIONELLA PNEUMOPHILA; MENINGOCOCCOSIS; MOLECULAR CLONING; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BLOOD BACTERICIDAL ACTIVITY; BLOTTING, WESTERN; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; MACROPHAGES; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; MICE; MICE, INBRED BALB C; NEISSERIA MENINGITIDIS, SEROGROUP B; RABBITS; RECOMBINANT PROTEINS; SERUM BACTERICIDAL ANTIBODY ASSAY; VACCINES, SYNTHETIC;

EID: 80052313162     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.05019-11     Document Type: Article

References (59)

1. Bangsborg, J. M., G. Shand, E. Pearlman, and N. Hoiby. 1991. Cross-reactive Legionella antigens and the antibody response during infection. APMIS 99:854-865.
2. Borrow, R., and E. Miller. 2006. Long-term protection in children with meningococcal C conjugate vaccination: lessons learned. Expert Rev. Vaccines 5:851-857.
3. Callaghan, M. J., et al. 2011. Potential of recombinant Opa proteins as vaccine candidates against hyperinvasive meningococci. Infect. Immun. 79: 2810-2818.
4. Casella, C. R., and T. C. Mitchell. 2008. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell. Mol. Life Sci. 65:3231-3240.
5. Christodoulides, M., J. L. Brooks, E. Rattue, and J. E. Heckels. 1998. Immunisation with recombinant class 1 outer membrane protein from Neisseria meningitidis: influence of liposomes and adjuvants on antibody avidity, recognition of native protein and the induction of a bactericidal immune response against meningococci. Microbiology 144:3027-3037.
6. Christodoulides, M., K. Jolley, and J. E. Heckels. 2001. Recombinant proteins in vaccine development, p. 167-180. In A. J. Pollard and M. C. J. Maiden (ed.), Meningococcal vaccines. Humana Press, Totowa, NJ.
7. Christodoulides, M., B. T. McGuinness, and J. E. Heckels. 1993. Immunisation with synthetic peptides containing epitopes of the class 1 outer membrane protein of Neisseria meningitidis: production of bactericidal antibodies on immunisation with a cyclic peptide. J. Gen. Microbiol. 139:1729-1738.
8. Cianciotto, N. P., B. I. Eisenstein, C. H. Mody, G. B. Toews, and N.C. Engleberg. 1989. A Legionella pneumophila gene encoding a species-specific surface protein potentiates initiation of intracellular infection. Infect. Immun. 57:1255-1262.
9. Cianciotto, N. P., W. Oconnell, G. A. Dasch, and L. P. Mallavia. 1995. Detection of MIP-like sequences and MIP-related proteins within the family Rickettsiaceae. Curr. Microbiol. 30:149-153.
10. Dornan, J., P. Taylor, and M. D. Walkinshaw. 2003. Structures of immunophilins and their ligand complexes. Curr. Top. Med. Chem. 3:1392-1409.
11. Echenique-Rivera, H., et al. 2011. Transcriptome analysis of Neisseria meningitidis in human whole blood and mutagenesis studies identify virulence factors involved in blood survival. PLoS Pathog. 7:e10002027.
12. Findlow, J., et al. 2010. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin. Infect. Dis. 51:1127-1137.
13. Finne, J., M. Leinonen, and P. H. Makela. 1983. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet ii:355-357.
14. Fischer, G., H. Bang, B. Ludwig, K. Mann, and J. Hacker. 1992. MIP protein of Legionella pneumophila exhibits peptidyl-prolyl-cis trans isomerase (PPIase) activity. Mol. Microbiol. 6:1375-1383.
15. Fletcher, L. D., et al. 2004. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect. Immun. 72:2088-2100.
16. Fretz, H., et al. 1991. Rapamycin and Fk506 binding-proteins (immunophilins). J. Am. Chem. Soc. 113:1409-1411.
17. Giuliani, M. M., et al. 2006. A universal vaccine for serogroup B meningococcus. Proc. Natl. Acad. Sci. U. S. A. 103:10834-10839.
18. Goldschneider, I., E. C. Gotschlich, and M. S. Artenstein. 1969. Human immunity to the meningococcus. II. Development of natural immunity. J. Exp. Med. 129:1327-1348.
19. Granoff, D. M. 2010. Review of meningococcal group B vaccines. Clin. Infect. Dis 50:S54-S65.
20. Hacker, J., and G. Fischer. 1993. Immunophilins-structure-function relationship and possible role in microbial pathogenicity. Mol. Microbiol. 10:445-456.
21. Heckels, J. E. 1981. Structural comparison of Neisseria gonorrhoeae outer membrane proteins. J. Bacteriol. 145:736-742.
22. Helbig, J. H., et al. 2003. The PPIase active site of Legionella pneumophila MIP protein is involved in the infection of eukaryotic host cells. Biol. Chem. 384:125-137.
23. Helbig, J. H., P. C. Luck, M. Steinert, E. Jacobs, and M. Witt. 2001. Immunolocalization of the MIP protein of intracellularly and extracellularly grown Legionella pneumophila. Lett. Appl. Microbiol. 32:83-88.
24. Hitchcock, P. J., and T. M. Brown. 1983. Morphological heterogeneity among Salmonella lipopolysaccharide chemotypes in silver-stained polyacrylamide gels. J. Bacteriol. 154:269-277.
25. Holst, J., et al. 2009. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 27:B3-B12.
26. Horne, S. M., T. J. Kottom, L. K. Nolan, and K. D. Young. 1997. Decreased intracellular survival of an fkpA mutant of Salmonella typhimurium Copenhagen. Infect. Immun. 65:806-810.
27. Humphries, H., et al. 2006. Multivalent liposome-based vaccines containing different serosubtypes of PorA protein induce cross-protective bactericidal immune responses against Neisseria meningitidis. Vaccine 24:35-44.
28. Idanpaan-Heikkila, I., et al. 1995. The antibody response to a prototype liposome vaccine containing Neisseria meningitidis outer membrane protein P1 produced in Bacillus subtilis. Vaccine 13:1501-1508.
29. Idanpaan-Heikkila, I., et al. 1996. Immunization with meningococcal class 1 outer membrane protein produced in Bacillus subtilis and reconstituted in the presence of Zwittergent or Triton X-100. Vaccine 14:886-891.
30. Jiang, H. Q., et al. 2010. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 28:6086-6093.
31. Jolley, K., L. Appleby, J. C. Wright, M. Christodoulides, and J. E. Heckels. 2001. Immunisation with recombinant Opc outer membrane protein from Neisseria meningitidis: influence of sequence variation and levels of expression on the bactericidal immune response against meningococci. Infect. Immun. 69:3809-3916.
32. Jordens, J. Z., J. N. Williams, G. R. Jones, M. Christodoulides, and J. E. Heckels. 2004. Development of immunity to serogroup B meningococci during carriage of Neisseria meningitidis in a cohort of university students. Infect. Immun. 72:6503-6510.
33. Kohler, R., et al. 2003. Biochemical and functional analyses of the MIP protein: influence of the N-terminal half and of peptidylprolyl isomerase activity on the virulence of Legionella pneumophila. Infect. Immun. 71:4389-4397.
34. Leuzzi, R., et al. 2005. Ng-MIP, a surface-exposed lipoprotein of Neisseria gonorrhoeae, has a peptidyl-prolyl cis/trans isomerase (PPIase) activity and is involved in persistence in macrophages. Mol. Microbiol. 58:669-681.
35. Lundemose, A. G., S. Birkelund, S. J. Fey, P. M. Larsen, and G. Christiansen. 1991. Chlamydia trachomatis contains a protein similar to the Legionella pneumophila MIP gene-product. Mol. Microbiol. 5:109-115.
36. Martin, D. R., N. Ruijne, L. McCallum, J. O'Hallahan, and P. Oster. 2006. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin. Vaccine Immunol. 13:486-491.
37. McGuinness, B. T., et al. 1991. Point mutation in meningococcal porA gene associated with increased endemic disease. Lancet 337:514-517.
38. Milagres, L. G., M. C. Gorla, C. T. Sacchi, and M. A. Rodrigues. 1998. Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunisation with an outer membrane vaccine. Infect. Immun. 66:4755-4761.
39. Mo, Y. Y., J. Seshu, D. Wang, and L. P. Mallavia. 1998. Synthesis in Escherichia coli of two smaller enzymically active analogues of Coxiella burnetii macrophage infectivity potentiator (CbMIP) protein utilizing a single open reading frame from the cbmip gene. Biochem. J. 335:67-77.
40. Moro, A., F. Ruizcabello, A. Fernandezcano, R. P. Stock, and A. Gonzalez. 1995. Secretion by Trypanosoma cruzi of a peptidyl-prolyl cis-trans isomerase involved in cell infection. EMBO J. 14:2483-2490.
41. Nordly, P., E. M. Agger, P. Andersen, H. M. Nielsen, and C. Foged. 2011. Incorporation of the TLR4 agonist monophosphoryl lipid A into the bilayer of DDA/TDB liposomes: physico-chemical characterization and induction of CD8(+) T-cell responses in vivo. Pharm. Res. 28:553-562.
42. Pereira, P. J. B., et al. 2002. Trypanosoma cruzi macrophage infectivity potentiator has a rotamase core and a highly exposed alpha-helix. EMBO Rep. 3:88-94.
43. Perrie, Y., A. R. Mohammed, D. J. Kirby, S. E. Mcneil, and V. W. Bramwell. 2008. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int. J. Pharm. 364:272-280.
44. Riboldi-Tunnicliffe, A., et al. 2001. Crystal structure of MIP, a prolylisomerase from Legionella pneumophila. Nat. Struct. Biol. 8:779-783.
45. Richmond, P., et al. 2010. Safety and immunogenicity of serogroup B Neisseria meningitidis (MnB) rLP2086 vaccine in adults and adolescent subjects: overview of 3 clinical trials, Abstr. VWO4. In Abstr. 17th Int. Pathog. Neisseria Conf. 2010, Banff, Alberta, Canada.
46. Rinaudo, C. D., J. L. Telford, R. Rappuoli, and K. L. Seib. 2009. Vaccinology in the genome era. J. Clin. Invest. 119:2515-2525.
47. Rockey, D. D., B. B. Chesebro, R. A. Heinzen, and T. Hackstadt. 1996. A 28 kDa major immunogen of Chlamydia psittaci shares identity with MIP proteins of Legionella spp and Chlamydia trachomatis-cloning and characterization of the C-psittaci MIP-like gene. Microbiology 142:945-953.
48. Schagger, H., and G. von Jagow. 1987. Tricine-sodium dodecyl sulphatepolyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal. Biochem. 166:368-379.
49. Schreiber, S. L. 1991. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 251:283-287.
50. Siekierka, J. J., et al. 1990. The cytosolic-binding protein for the immunosuppressant Fk-506 is both a ubiquitous and highly conserved peptidyl-prolyl cis-trans isomerase. J. Biol. Chem. 265:21011-21015.
51. Verma, J. N., et al. 1992. Adjuvant effects of liposomes containing lipidA-enhancement of liposomal antigen presentation and recruitment of macrophages. Infect. Immun. 60:2438-2444.
52. Vermont, C., and G. van den Dobbelsteen. 2002. Neisseria meningitidis serogroup B: laboratory correlates of protection. FEMS Immunol. Med. Microbiol. 34:89-96.
53. Vogtherr, M., et al. 2002. NMR solution structure and dynamics of the peptidylprolyl cis-trans isomerase domain of the trigger factor from Mycoplasma genitalium compared to FK506-binding protein. J. Mol. Biol. 318: 1097-1115.
54. Wetzler, L. M., M. S. Blake, K. Barry, and E. C. Gotschlich. 1992. Gonococcal porin vaccine evaluation-comparison of por proteosomes, liposomes, and blebs isolated from rmp deletion mutants. J. Infect. Dis. 166: 551-555.
55. Wieland, H., M. Faigle, F. Lang, H. Northoff, and B. Neumeister. 2002. Regulation of the Legionella MIP promotor during infection of human monocytes. FEMS Microbiol. Lett. 212:127-132.
56. Williams, J. N., G. R. Jones, M. Christodoulides, and J. E. Heckels. 2003. Serological correlates of protection against meningococci in a cohort of university students before and during an outbreak of serogroup C infection. J. Infect. Dis. 187:1433-1441.
57. Williams, J. N., et al. 2007. Proteomic analysis of outer membranes and vesicles from wild-type serogroup B Neisseria meningitidis and a lipopolysaccharide-deficient mutant. Infect. Immun. 75:1364-1372.
58. Williams, J. N., P. J. Skipp, C. D. O'Connor, M. Christodoulides, and J. E. Heckels. 2009. Immunoproteomic analysis of the development of natural immunity in subjects colonized by Neisseria meningitidis reveals potential vaccine candidates. Infect. Immun. 77:5080-5089.
59. Wright, J. C., J. N. Williams, M. Christodoulides, and J. E. Heckels. 2002. Immunisation with recombinant PorB outer membrane protein induces a bactericidal immune response against Neisseria meningitidis. Infect. Immun. 70:4028-4034.